Fig. 7: Therapeutic efficacy of human cardiac tissue transplantation for improving cardiac function after myocardial infarction. | Nature Communications

Fig. 7: Therapeutic efficacy of human cardiac tissue transplantation for improving cardiac function after myocardial infarction.

From: Versatile human cardiac tissues engineered with perfusable heart extracellular microenvironment for biomedical applications

Fig. 7

a Schematic illustration of transplantation of cardiac tissues containing human induced pluripotent stem cell (hiPSC)-derived RFP+ cardiomyocytes (CMs) in a rat model of myocardial infarction induced by left anterior descending (LAD) ligation and reperfusion. b Representative echocardiography images of M-mode in three groups at baseline (1 week after myocardial infarction) and 6 weeks post-transplantation. c Quantification of left ventricular ejection fraction (LVEF), left ventricular fractional shortening (LVFS), d left ventricular internal diameter end-diastole (LVIDd), left ventricular internal diameter end-systole (LVIDs), e septal wall thickness (SWT), and posterior wall thickness (PWT) values (N = 5 for No treatment and N = 7 for No HEM-Ps and HEM-Cf, biological replicates, *p < 0.05, **p < 0.01, and ***p < 0.001 versus No treatment group, #p < 0.05, ##p < 0.01, and ###p < 0.001 versus No HEM-Ps group). f Representative graph of the hemodynamic pressure and volume (PV) curve during steady state at 4 weeks post-transplantation. g Quantitative graphs of cardiac output, stroke volume, h maximal rate of pressure changes during systole (dP/dtmax), minimal rate of pressure changes during diastole (dP/dtmin), and maximum volume (Vmax) at end-diastole (N = 5, biological replicates, ***p < 0.001 versus No treatment group, ##p < 0.01 and ###p < 0.001 versus No HEM-Ps group). i Quantitative graphs of the slope of end-systolic pressure-volume relationship (ESPVR) and the slope of the end-diastolic pressure-volume relationship (EDPVR) (N = 4 for No treatment and N = 5 for No HEM-Ps and HEM-Cf, biological replicates, **p < 0.01 versus No treatment group, #p < 0.05 versus No HEM-Ps group). Cardiac tissues prepared with hiPSC-derived RFP+ CMs, cardiac fibroblasts (CFs), and human umbilical vein endothelial cells (HUVECs) were cultured under each condition for 9 days and used for transplantation. Data are presented as means ± S.D. Statistical significance was determined using one-way ANOVA with Bonferroni’s multiple comparison tests in (c, d, e, and i) and Tukey’s multiple comparisons tests in (g and h).

Back to article page